HUTCHMED (00013) Jinpu Health Equity Investment Management Designated Shanghai Jinpu Zhicheng Private Equity Fund Partnership Enterprise and Shanghai Jinpu Zhibaihe Enterprise Management Partnership Enterprise as the buyer.

HUTCHMED (00013) announced on February 28, 2025 that, according to the Jinpu Health Service Purchase Agreement, Shanghai Jinpu Zhicheng Private Equity Fund Partnership Enterprise (Limited Partnership) (as the buyer fund of Jinpu Health Service) and Shanghai Jinpu Zhi Bai Enterprise Management Partnership Enterprise (Limited Partnership) (as the designated buyer) will respectively purchase 25.1247% and 9.8753% of the equity of Shanghai and Huang Pharmaceutical Industry, totaling the entire shares of Jinpu Health Service for sale. Given the strong business foundation that the company has built in China over the past two decades, the company plans to reinvest the proceeds from the proposed sale into its operations in China. This sale will facilitate resource allocation, allowing these resources to be reallocated to the company's innovative initiatives in China, particularly those aimed at strengthening its research and development capabilities and expanding its production and commercial infrastructure. This strategic focus will enable the company to better seize future development opportunities.